F
Fred R. Hirsch
Researcher at University of Colorado Denver
Publications - 401
Citations - 33536
Fred R. Hirsch is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Lung cancer & Large Hadron Collider. The author has an hindex of 85, co-authored 362 publications receiving 31524 citations. Previous affiliations of Fred R. Hirsch include Mount Sinai Health System.
Papers
More filters
Proceedings ArticleDOI
7.1.1 Invited: Chemical Nanoarrays for Early Detection and Screening of Lung Cancer via Volatile Biomarkers
Hossam Haick,Orna Barash,Marwan Hakim,Ulrike Tisch,Radu Ionescu,Paul A. Bunn,Jane Mattei,York E. Miller,Timothy C. Kennedy,John D. Mitchell,Michael J. Weyant,Fred R. Hirsch,Nir Peled,Maya Ilouze +13 more
TL;DR: An artificial electronic nose that makes use of cross-reactive chemical sensor nanoarrays, for the detection of volatile biomarkers in breath samples as well as in the headspace of in-vitro cell lines of lung cancer.
Journal ArticleDOI
The presence of circulating genetically abnormal cells in blood predicts risk of lung cancer in individuals with indeterminate pulmonary nodules
Shahram Tahvilian,J. Kuban,David F. Yankelevitz,Daniel Leventon,Claudia I. Henschke,Jeffrey Zhu,Lara Baden,Rowena Yip,Fred R. Hirsch,Benjamin A. Katchman,Michael J. Donovan,Paul Pagano +11 more
TL;DR: LungLB™ as mentioned in this paper is a 4-color fluorescence in-situ hybridization assay for detecting circulating genetically abnormal cells (CGACs) that are present early in lung cancer pathogenesis.
Journal ArticleDOI
M06-03: Prediction of benefit from EGFR TKIs by proteomic analysis of pretreatment serum
Fumiko Taguchi,Benjamin Solomon,Vanesa Gregorc,Heinrich Roder,Robert Gray,Kazuo Kasahara,Makoto Nishi,Julie R. Brahmer,Anna Spreafico,Vienna Ludovini,Pierre P. Massion,Rafal Dziadziuszko,Joan H. Schiller,Julia Grigorieva,Maxim Tsypin,Stephen W. Hunsucker,Richard M. Caprioli,Mark W. Duncan,Fred R. Hirsch,Paul A. Bunn,David P. Carbone +20 more
Proceedings ArticleDOI
Subtype-specific transcription factors are clinically relevant and show distinct therapeutic vulnerabilities in human small cell lung cancer
C. Lang,Zsolt Megyesfalvi,B. Szeitz,A. Lantos,Nicole Woldmar,Zsuzsanna Valko,A. Schwendenwein,Felicitas Oberndorfer,Nándor Bárány,Sándor Paku,Viktoria Laszlo,Helga Kiss,Edina Bugyik,B. Ferencz,Katalin Dezső,Zoltan Lohinai,Judit Moldvay,János Fillinger,Gabriela Galffy,Christopher J. Rivard,Fred R. Hirsch,Luka Brcic,H. Popper,Izidor Kern,M. Kovacevic,Jeremy Skarda,Marcel Mitták,Attila Marcell Szász,Luciana Pizzatti,Krisztina Bogos,MA Hoda,Konrad Hoetzenecker,Gyoergy Marko-Varga,P. Horvatovics,Ferenc Rényi-Vámos,Thomas Klikovits,Karin Schelch,Melinda Rezeli,B Döme +38 more
TL;DR: In this paper , the authors investigated the clinical presence and therapeutic relevance of ASCL1, NEUROD1, POU2F3, YAP1 in small cell lung cancer (SCLC) patients.
Journal ArticleDOI
Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?
N. Meshulami,Sooyun Tavolacci,Diego de Miguel-Perez,Christian Rolfo,Philip C. Mack,Fred R. Hirsch +5 more
TL;DR: In this article , the authors analyzed 17 phase-III clinical studies and a retrospective study to determine if the predictive capability of PD-L1 expression varies between squamous and nonsquamous NSCLC.